Posts Tagged ‘x57l’

Buy and sell used stuff

August 2, 2017

https://us.letgo.com/enhttps://offerup.com/

2 Ways to Use a Custom Domain with Dropbox – fredericiana

July 25, 2017

http://fredericiana.com/2012/12/09/custom-domain-with-dropbox/

QT:{{"

Option 2: CNAME

There’s another option that doesn’t require any changes to your server. However, you’ll need access to your provider’s DNS settings.

If you do have such access, you can create a DNS CNAME record. A CNAME record is essentially a domain alias, forwarding one domain name to another.

It’s pretty simple:

  1. Access your provider’s DNS settings menu. Providers should have a help file about how to do this, like this one from Hover.
  2. Add a new DNS record, type: CNAME.
  3. Choose a domain name (such as i.example.com) and point it to dl.dropbox.com.

Once the changes have been picked up by the DNS system, you’re done! Your screenshots will be available under a URL like: http://i.example.com/u/XYZ/Screenshots/abcd.png.

While certainly elegant, one (big) caveat of this solution is that the resulting URLs still contain the portion /u/XYZ/Screenshots. Because the CNAME record works purely on a domain level, there is no way for us to hide this portion of the URLs with this method.

"}}

IBM Watson Developer Cloud

July 18, 2017

https://www.ibm.com/watson/developercloud/

Post-transcriptional regulation across human tissues

July 16, 2017

Post-transcriptional reg…across…tissues [v genes], by @SlavovLab http://journals.PLoS.org/ploscompbiol/article?id=10.1371/journal.pcbi.1005535 Simpson’s paradox! Diff in protein-mRNA corr.

Set Up, Manage and Protect Apple Devices at Work | Jamf Now

July 14, 2017

https://www.jamf.com/lp/set-up-manage-and-protect-apple-devices-at-work

AI for drug discovery – cyan

July 4, 2017

Make Pharma Great Again w. AI, by @mostafabenh
https://Medium.com/@mostafab/make-pharma-great-again-with-artificial-intelligence-some-challenges-50e91ea9988d Optimism-inducing Moore’s law in tech vs. #Eroom’s law for drugs

QT:{{”
Drug discovery is getting increasingly tough and expensive. Despite technological progress, the cost of developing a new drug doubles every nine years. That’s Eroom’s law of Pharma, which mirrors Moore’s law for computer performance.

….

Drugs are getting more expensive

In the tech industry, the situation is different. Optimism prevails. Tech is fueled by Moore’s law, the fact that computer performance is doubling every 18 months.

Moore’s law

This exponential progress keeps prices low. For example, Google gives away the use of its new TPU chip for free, for some scientific projects. Tech companies are more generous due to their feeling of abundance. How can Tech help Pharma, especially at a time of expansion for Artificial Intelligence?
“}}

‘Make Pharma Great Again with Artificial Intelligence: some Challenges’

https://medium.com/@mostafab/make-pharma-great-again-with-artificial-intelligence-some-challenges-50e91ea9988d

Clues from the resilient

July 4, 2017

Clues from the resilient
http://www.ScienceMag.org/content/344/6187/970.full Potential 2nd site mutations that neutralize #Mendelian-disease mutations

QT:{{”
“For 127 catastrophic Mendelian diseases (those caused by a single gene such as cystic fibrosis and ataxia-telangiectasia), there are presently 164 genes harboring 685 known recurrent variants that are highly penetrant and causal for deleterious traits, most typically manifesting in individuals before the age of 18 (). …For common diseases, the observed small effect sizes of individual gene variants limit diagnostic potential, and given that most variants identified have an unclear function, how to target the corresponding gene for therapeutic intervention is typically unclear. For rarer Mendelian disorders, although genetics directly implicate a specific gene in a disease, a majority of such cases relate to loss-of-function mutations. Designing small molecules to fix the corresponding broken protein has proven difficult….
The prominent role of second-site mutations and environmental factors that enable resistance to (or buffer against) disease traits has been well established in a multitude of model organisms from yeast to mice (–). Screening for second-site mutations in “resilient” individuals that prevent disease-causing alleles from manifesting their effects could identify targets to which drugs would be designed to disrupt their function, as opposed to targeting the disease-causing gene directly. Genetic studies examining seemingly healthy people have revealed, for example, rare mutations in chemokine (C-C motif) receptor type 5 (the co-receptor for human immunodeficiency virus) that block HIV infection (), and secondary mutations in fetal globin genes that modify the severity of sickle cell disease by buffering primary mutations in β-globin genes ()
“}}

Kyoto Prize – Wikipedia

July 3, 2017

https://en.wikipedia.org/wiki/Kyoto_Prize

FYI – Personalized Medicine: Redefining Cancer Treatment

July 3, 2017

https://www.kaggle.com/c/msk-redefining-cancer-treatment

List of collaboration tools

July 3, 2017

Thought the below was an interesting snippet from a dialogue I had….

QT:{{”

Collaboration tools: Even a small group…will quickly get unwieldy if we coordinate using long CC-chains on email threads.

I think the minimum requirements are central management, email lists, and document sharing.

Options that come to mind are:
– Google G-suite, Drive, and Groups (free for nonprofits, robust features, integrate with existing login…)
– Slack plus Dropbox (more suited for teams who are actively collaborating, but it could be a great framework)
– Yammer (looks great, but I’ve never really used it)
– Office365 (it’s heavyweight and costs money, but it’ll give us all the features we could ever imagine)
– Basecamp (I haven’t used it in years, and it’s more about project management than collaboration)

“}}